多西他赛联合奥沙利铂并同步放疗治疗局部晚期宫颈鳞癌的疗效观察

doi:10.3969/j.issn.1671-7171.2017.03.008

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the clinical efficacy of docetaxel combined with oxaliplatin chemotherapy concurrent with radiotherapy for advanced cervical squamous-cell carcinoma. 【Methods】One hundred and twenty-five patients with locally advanced cervical squamous carcinoma in our hospital between July 2013-January 2015 were selected as the research subject. According to different therapeutic methods, patients were divided into the cisplatin group (59 cases) and Docetaxel＆Oxaliplatin group (TP group, 66 cases). The cisplatin group was given cisplatin chemotherapy concurrent with radiation therapy, while TP group was given docetaxel combined with oxaliplatin chemotherapy concurrent with radiotherapy. The curative effect and adverse reactions between the two groups were observed. 【Results】The total effective rate of TP group was 93.9% (62/66), which was significantly higher than that of the cisplatin group (81.3%, 48/59); the difference was statistically significant (P<0.05). The occurrence of gastrointestinal reaction, myelosuppression, radiation proctitis, and radiocystitis of TP group were 83.3%, 98.5%, 95.5% and 66.7%, respectively, while those in the cisplatin group were 91.5%, 96.6%, 91.5%, and 54.2%, respectively. There were no significantly statistical differences between the two groups (P>0.05). 【Conclusion】Docetaxel combined with oxaliplatin chemotherapy concurrent with radiotherapy for locally advanced cervical squamous cell carcinoma is both safe and effective.

Key words： Taxoids/TU Organoplatinum Compounds/TU Uterine Cervical Neoplasms/RT Carcinoma, Squamous Cell/RT Uterine Cervical Neoplasms/DT Carcinoma, Squamous Cell/DT

Received: 26 October 2015

PACS:

R737.33

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2017.03.008 OR http://www.jcr.net.cn/EN/Y2017/V34/I3/441

[1] Luciani S, Cabanes A, Prieto-Lara E,et al. Cervical and female Breast cancers in the Americas:current situation and opportunities for action[J].Bull World Health Organ,2013, 91(9):640-649.
[2] 胡尚英,郑荣寿,赵方辉,等.1989至2008年中国女性子宫颈癌发病和死亡趋势分析[J].中国医学科学院学报,2014,36(2):119-125.
[3] Kato S, Ohno T, Thephamongkhol K, et al. Long-term follow-up results of a multi-institutional phase 2 study of concurrent chemoradiation therapy for locally advanced cervical cancer in east and southeast Asia [J].Int J Radiat Oncol Biol Phys,2013,87(1):100-105.
[4] Al Asiri M, Tunio M, Al Hadab A, et al. Five-year outcome of concurrent radiotherapy and chemotherapy in Saudi women with locally advanced cervical cancer:single-institution experience[J].Ann Saudi Med,2013,33(4):327-333.
[5] Jang HJ,Kim BC,Kim HS,et al. Comparison of RECIST 1.0 and RECIST 1.1 on computed tomography in patients with metastatic colorectal cancer [J].Oncology,2014,86(2): 117.
[6] Kanazawa K,Yokouchi H,Wang X,et al. Phase II trial of carboplatin and pemetrexed as first line chemotherapy for non-squamous non-small cell lung cancer,and correlation between the efficacy /toxicity and genetic polymorphisms associated with pemetrexed metabolism:Hokkaido Lung Cancer Clinical Study Group Trial ( HOT)0902 [J].Cancer Chemother Pharmacol,2014,74(6): 1149-1157.
[7] Granados Lopez AJ, Lopez JA. Mutistep Model of Cervical Cancer: Participation of miRNAs and Coding Genes[J].Int J Mol Sci,2014,15(9):15700-15733.
[8] 王楠,马蓉,吴建中,等. 宫颈癌的发病机制、诊断及治疗进展[J].中国肿瘤外科杂志,2013,5(2):121-124.
[9] 黄晶,张才友,丁金泉,等. 参芪扶正注射液联合放化疗治疗中晚期宫颈癌的疗效分析[J].赣南医学院学报,2014,34(6):885-887.
[10] 尹彩云. 紫杉醇联合奈达铂用于宫颈癌根治术前新辅助化疗的近期疗效分析〔J〕.中国医学创新,2014,11(19): 130-132.
[11] 高岩,张新,王纯雁.同步放化疗治疗中晚期宫颈癌的疗效及副反应[J].中国肿瘤,2013,22(1):73-76.
[12] Silva IH, Nogueira-Silva C, Figueiredo T, et al. The impact of GGH-401C > T polymorphism on cisplatin based chemoradiotherapy response and survival in cervical cancer [J].Gene,2013, 512(2): 247-250.
[13] 乔林邦, 刘淑媛, 张永喜. 奈达铂联合多西他塞治疗晚期非小细胞肺癌的临床观察 [J].当代医学, 2013,19(18): 141-142.
[14] Pu J,Qin SS,Ding JX,et al. A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel /cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery[J].J Cancer Res Clin Oncol,2013,139( 4) : 703-708.
[15] 尚品杰.奥沙利铂或伊立替康联合卡培他滨治疗晚期转移性肠癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(24):2396-2398.
[16] Oh IJ, Kim KS, Kim YC,et al.A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or do cetaxel or gemcitabine in unresectable Non-small cell lung cancer: KASLC 0401[J].Cancer Chemother Pharmacol,2013,72( 6) : 1247-1254.
[17] 徐云. 洛铂联合多西他赛治疗80例宫颈癌的疗效观察[J].临床医药文献杂志,2015,2(8):1530-1531.
[18] 蔡秋玲. 周剂量多西他赛结合低剂量顺铂治疗高龄患者晚期非小细胞肺癌的效果[J].临床医学,2016,36(8):24-27.
[19] 王涛,赵磊,李榆,等. 周剂量多西他赛联合顺铂与周剂量多西他赛联合奥沙利铂治疗晚期胃癌的临床研究[J].中国癌症杂志,2015,25( 2) : 150-154.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2017, 34(3): 553-555.